Haemophilus Influenzae Type b Conjugate Vaccine (Hib) is the first product developed independently by Walvax. Walvax obtained the Drug Registration Approval issued by the State Food and Drug Administration (SFDA) on April 1st, 2007 (No.: 2007S00061, Drug Approval No.: Guoyao Zhunzi S20070010). Walvax obtained the New Drug Certificate issued by the SFDA on April 2, 2007 (certificate number: GYZZ S20070007), the product officially launched into market in September 2007.
Haemophilus Influenzae Type b Conjugate Vaccine is a preparation of Haemophilus influenzae type b 58534 strain capsular polysaccharide antigen obtained through fermentation and purification, activation and derivatization covalently bound to tetanus toxoid protein. This vaccine is indicated for infants from the age of 2 months to 5 years to induce the active immunization against infectious diseases caused by Haemophilus influenzae type b, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis etc.